1. Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells.
- Author
-
Lee JM, Shin KS, Koh CH, Song B, Jeon I, Park MH, Kim BS, Chung Y, and Kang CY
- Subjects
- Animals, Antigens, Ly immunology, CD11c Antigen immunology, Cancer Vaccines immunology, Cancer Vaccines pharmacology, Cell Proliferation genetics, Coculture Techniques, Combined Modality Therapy, Dendritic Cells drug effects, Dendritic Cells immunology, Humans, Immunity, Innate drug effects, Immunity, Innate immunology, Lymphocytes, Tumor-Infiltrating drug effects, Lymphocytes, Tumor-Infiltrating immunology, Mice, Neoplasms immunology, Neoplasms pathology, Receptors, IgG immunology, T-Lymphocytes immunology, Topoisomerase I Inhibitors immunology, Topotecan pharmacology, Tumor Microenvironment drug effects, Tumor Microenvironment immunology, Antigen-Presenting Cells immunology, Immunotherapy, Neoplasms therapy, Topoisomerase I Inhibitors pharmacology
- Abstract
Understanding the rationale of combining immunotherapy and other anticancer treatment modalities is of great interest because of interpatient variability in single-agent immunotherapy. Here, we demonstrated that topoisomerase I inhibitors, a class of chemotherapeutic drugs, can alter the tumor immune landscape, corroborating their antitumor effects combined with immunotherapy. We observed that topotecan-conditioned TC-1 tumors were occupied by a vast number of monocytic cells that highly express CD11c, CD64, and costimulatory molecules responsible for the favorable changes in the tumor microenvironment. Ly6C
+ MHC-II+ CD11chi CD64hi cells, referred to as topotecan-induced monocyte-derived dendritic cells (moDCs), proliferate and activate antigen-specific CD8+ T cells to levels equivalent to those of conventional DCs. Phenotypic changes in Ly6C+ cells towards moDCs were similarly induced by exposure to topotecan in vitro, which was more profoundly facilitated in the presence of tumor cells. Notably, anti-M-CSFR reversed the acquisition of DC-like properties of topotecan-induced moDCs, leading to the abolition of the antitumor effect of topotecan combined with a cancer vaccine. In short, topoisomerase I inhibitors generate monocyte-derived antigen-presenting cells in tumors, which could be mediated by M-CSF-M-CSFR signaling., (Copyright © 2021 Elsevier B.V. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF